-Advertisement-
-Advertisement-
FDA Alerts
Hematology
Metabolic
Trending Topics

FDA Approves New Treatment for Adults with Cushing’s Disease

Posted on June 1, 2020
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

The US FDA has approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. This is the first FDA-approved drug to directly address cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.

Osilodrostat had previously received Orphan Drug Designation.

“The FDA supports the development of safe and effective treatments for rare diseases, and this new therapy can help people with Cushing’s disease, a rare condition where excessive cortisol production puts them at risk for other medical issues,” said Mary Thanh Hai, MD, acting director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research said in a press release. “By helping patients achieve normal cortisol levels, this medication is an important treatment option for adults with Cushing’s disease.”

-Advertisement-
Related Articles
Society for InherIted Metabolic Disorders Provides Update on Annual Meeting Amidst COVID-19 Outbreak
Jun 02, 2020
FDA Grants Rare Pediatric Disease Designation for Barth Syndrome Treatment
May 31, 2020
FDA Grants Rare Pediatric Disease Designation for Barth Syndrome Treatment
Mar 16, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-